Tirzepatide's dual receptor mechanism How tirzepatide works: Dual GIP/GLP-1 receptor agonist Single molecule, two pathways GIP (glucose-dependent insulinotropic polypeptide) + GLP-1 Weekly subcutaneous injection FDA approved for diabetes and obesity GIP pathway effects: Enhances insulin secretion Improves insulin sensitivity Promotes fat metabolism Reduces inflammation Works synergistically with GLP-1 GLP-1 pathway effects: Suppresses appetite (central brain effects) Slows gastric emptying (moderate) Increases satiety Reduces glucagon Improves glucose control Combined tirzepatide results: 15-22% average body weight loss (monotherapy) Superior to semaglutide (GLP-1 alone) Well-tolerated in trials Approved and available See our tirzepatide dosing guide , semaglutide vs tirzepatide , and peptides for weight loss at SeekPeptides
Other populations at risk include people who had gastrointestinal surgery (including weight loss surgery) and diseases that affect the gut, such as Crohn's disease or celiac disease
Dr Abdullah has had patients coming in with side effects like extreme nausea, debilitating headaches, fluid retention, hypertension, anxiety, rapid heart rate, abnormal glucose levels, and depression
ShimpiS.ChauhanB.ShimpiP.2005Cyclodextrins: application in different routes of drug administration.552139156
A comprehensive protocol might include: Daily peptide shampoo and conditioner for topical peptide delivery during regular hygiene
